1. Home
  2. ELUT vs CDLX Comparison

ELUT vs CDLX Comparison

Compare ELUT & CDLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ELUT
  • CDLX
  • Stock Information
  • Founded
  • ELUT 2015
  • CDLX 2008
  • Country
  • ELUT United States
  • CDLX United States
  • Employees
  • ELUT N/A
  • CDLX N/A
  • Industry
  • ELUT Medical Specialities
  • CDLX Computer Software: Programming Data Processing
  • Sector
  • ELUT Health Care
  • CDLX Technology
  • Exchange
  • ELUT Nasdaq
  • CDLX Nasdaq
  • Market Cap
  • ELUT 94.0M
  • CDLX 96.6M
  • IPO Year
  • ELUT 2020
  • CDLX 2018
  • Fundamental
  • Price
  • ELUT $1.78
  • CDLX $1.79
  • Analyst Decision
  • ELUT Strong Buy
  • CDLX Hold
  • Analyst Count
  • ELUT 2
  • CDLX 5
  • Target Price
  • ELUT $8.00
  • CDLX $3.50
  • AVG Volume (30 Days)
  • ELUT 43.3K
  • CDLX 960.8K
  • Earning Date
  • ELUT 05-08-2025
  • CDLX 05-07-2025
  • Dividend Yield
  • ELUT N/A
  • CDLX N/A
  • EPS Growth
  • ELUT N/A
  • CDLX N/A
  • EPS
  • ELUT N/A
  • CDLX N/A
  • Revenue
  • ELUT $23,711,000.00
  • CDLX $272,588,000.00
  • Revenue This Year
  • ELUT $37.67
  • CDLX N/A
  • Revenue Next Year
  • ELUT $63.22
  • CDLX $6.10
  • P/E Ratio
  • ELUT N/A
  • CDLX N/A
  • Revenue Growth
  • ELUT N/A
  • CDLX N/A
  • 52 Week Low
  • ELUT $1.61
  • CDLX $1.22
  • 52 Week High
  • ELUT $5.24
  • CDLX $9.78
  • Technical
  • Relative Strength Index (RSI)
  • ELUT 41.19
  • CDLX 44.51
  • Support Level
  • ELUT $1.61
  • CDLX $1.81
  • Resistance Level
  • ELUT $1.89
  • CDLX $1.92
  • Average True Range (ATR)
  • ELUT 0.13
  • CDLX 0.12
  • MACD
  • ELUT 0.02
  • CDLX -0.03
  • Stochastic Oscillator
  • ELUT 31.22
  • CDLX 0.00

About ELUT Elutia Inc.

Elutia Inc Formerly Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The company's segments include Device Protection, Women's Health and Cardiovascular. It generates maximum revenue from the Women's Health segment. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection.

About CDLX Cardlytics Inc.

Cardlytics Inc operates an advertising platform within financial institutions' digital channels, which include online, mobile, email, and various real-time notifications. The company operates through segments namely, Cardlytics platform in the U.S. and U.K. and the Bridg platform. The Cardlytics platform segment which generates key revenue, operates a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels. The Bridg platform generates revenue through the sale of subscriptions to the cloud-based customer-data platform and the delivery of professional services like implementation, onboarding, and technical support. The company receives maximum revenue from the United States.

Share on Social Networks: